| Literature DB >> 20606912 |
Sitanshu Sekhar Kar1, Himanshu Sekhar Pradhan, Guru Prasad Mohanta.
Abstract
Entities:
Year: 2010 PMID: 20606912 PMCID: PMC2888334 DOI: 10.4103/0970-0218.62546
Source DB: PubMed Journal: Indian J Community Med ISSN: 0970-0218
Key factors for development of an essential medicines list
| Establishing a transparent process for creating and updating the list of essential medicines, provide a voice for key stakeholders, but ensure a scientific, evidence-based process |
| Linkage with standard clinical guidelines and involvement of both specialists and primary care providers |
| Garner support from senior clinicians, academic institutions, public health professionals, professional organizations, non-governmental organizations and community members |
| Making the list available (essential medicines, formulary manuals and clinical guidelines) in all health care facilities/health care providers in both printed and electronic format |
| Consider launching of new or revised lists with the involvement of concerned government officials with adequate publicity |
| Making clear the specific legal or administrative authority of the essential medicines list for training, procurement, reimbursement and public information |
| Establishing an administrative or budgetary “safety valve” for the limited supply and use of non-listed medicines |
| Regular Updating of the list so that it reflects therapeutic advances and changes in cost, resistance patterns and public health relevance |
Strategies to promote rational use of medicines
| A mandated multi-disciplinary national body to coordinate medicine use policies |
| Clinical guidelines |
| Essential medicines list based on treatments of choice |
| Drugs and therapeutics committees in districts and hospitals |
| Problem-based pharmacotherapy training in undergraduate curricula |
| Continuing in-service medical education as a licensure requirement |
| Supervision, audit and feedback |
| Independent information on medicines |
| Public education about medicines |
| Avoidance of perverse financial incentives |
| Appropriate and enforced regulation |
| Sufficient government expenditure to ensure availability of medicines and staff |